Salarius Pharmaceuticals Faces Delisting Concerns
Ticker: DCOY · Form: 8-K · Filed: Mar 28, 2025 · CIK: 1615219
Sentiment: bearish
Topics: delisting, material-agreement, regulatory
TL;DR
Salarius might be delisted, major red flag.
AI Summary
Salarius Pharmaceuticals, Inc. filed an 8-K on March 28, 2025, reporting a material definitive agreement and a notice of delisting or failure to meet continued listing standards. The company, formerly known as Flex Pharma, Inc., is based in Houston, TX.
Why It Matters
This filing indicates potential financial distress or non-compliance with exchange rules, which could significantly impact the company's stock trading and investor confidence.
Risk Assessment
Risk Level: high — The notice of delisting or failure to meet continued listing standards is a significant indicator of severe financial or operational challenges.
Key Players & Entities
- Salarius Pharmaceuticals, Inc. (company) — Registrant
- Flex Pharma, Inc. (company) — Former company name
- March 26, 2025 (date) — Date of earliest event reported
- March 28, 2025 (date) — Date of report
- 2450 Holcombe Blvd. Suite X Houston, TX 77021 (address) — Principal executive offices
FAQ
What is the specific reason for the notice of delisting or failure to meet continued listing standards?
The filing does not specify the exact reason for the notice of delisting or failure to meet continued listing standards, only that it is being reported.
What is the material definitive agreement that Salarius Pharmaceuticals entered into?
The filing indicates the entry into a material definitive agreement but does not provide details about the agreement itself.
When was Salarius Pharmaceuticals, Inc. formerly known as Flex Pharma, Inc.?
The company changed its name from Flex Pharma, Inc. on July 30, 2014.
What is the primary business of Salarius Pharmaceuticals, Inc.?
Salarius Pharmaceuticals, Inc. is in the business of Pharmaceutical Preparations, with SIC code 2834.
What is the SEC file number for Salarius Pharmaceuticals, Inc.?
The SEC file number for Salarius Pharmaceuticals, Inc. is 001-36812.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on March 28, 2025 regarding Salarius Pharmaceuticals, Inc. (DCOY).